Cargando…

The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial

BACKGROUND: Malignant pleural effusion (MPE) is one of the commonest causes of an exudative pleural effusion. Breathlessness, dyspnea and other symptoms often seriously distress and affect the quality of life. The external application of mirabilite and rhubarb (EAMR) combined with intrathoracic infu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Huachun, Jiang, Mengyuan, Gao, Lirong, Lin, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899874/
https://www.ncbi.nlm.nih.gov/pubmed/33607823
http://dx.doi.org/10.1097/MD.0000000000024758
_version_ 1783654100427079680
author Zhang, Huachun
Jiang, Mengyuan
Gao, Lirong
Lin, Zhen
author_facet Zhang, Huachun
Jiang, Mengyuan
Gao, Lirong
Lin, Zhen
author_sort Zhang, Huachun
collection PubMed
description BACKGROUND: Malignant pleural effusion (MPE) is one of the commonest causes of an exudative pleural effusion. Breathlessness, dyspnea and other symptoms often seriously distress and affect the quality of life. The external application of mirabilite and rhubarb (EAMR) combined with intrathoracic infusion of cisplatin, as an alternative treatment for MPE, is popular in China. The study aims to assess its effectiveness and safety combined with intrathoracic chemotherapy. METHODS: This study is a prospective, randomized controlled clinical trial. Patient visits were performed at baseline and days 14 and 28 after treatment. Clinical outcomes were measured after chest drain placement using the criterion of efficacy refer to WHO standard, and QLQ-C30 questionnaire. RESULTS: Database records of patients treated in our institution for MPE between October, 2016 and March, 2019. The study included 84 eligible patients. They were categorized with a randomization schedule into treatment group (N = 42) and control group (N = 42). There is statistical significance in the comparison of the total effective rate between these 2 groups (66.67% vs 54.76%, P < .05). Furthermore, there is statistical significance in the comparison of items of Physical (1.95 ± 0.50 vs 2.19 ± 0.58%, P < .05), Pain (1.98 ± 0.42 vs 2.07 ± 0.32, P < .05), and Global Health (1.23 ± 0.64 vs 1.13 ± 0.23%, P < .05) between these 2 groups. None of the patients had adverse reactions such as skin allergy and chest tightness. CONCLUSIONS: The total effective rate of treatment group using extra external application of mirabilite rhubarb powder is significantly higher than that of control group. The improvement of patients’ clinical symptoms is greater in treatment group and no adverse reactions is found. Therefore, external application of mirabilite and rhubarb combined with intrathoracic infusion of cisplatin is an effective method for the treatment of MPE, which is worth popularizing.
format Online
Article
Text
id pubmed-7899874
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-78998742021-02-24 The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial Zhang, Huachun Jiang, Mengyuan Gao, Lirong Lin, Zhen Medicine (Baltimore) 3800 BACKGROUND: Malignant pleural effusion (MPE) is one of the commonest causes of an exudative pleural effusion. Breathlessness, dyspnea and other symptoms often seriously distress and affect the quality of life. The external application of mirabilite and rhubarb (EAMR) combined with intrathoracic infusion of cisplatin, as an alternative treatment for MPE, is popular in China. The study aims to assess its effectiveness and safety combined with intrathoracic chemotherapy. METHODS: This study is a prospective, randomized controlled clinical trial. Patient visits were performed at baseline and days 14 and 28 after treatment. Clinical outcomes were measured after chest drain placement using the criterion of efficacy refer to WHO standard, and QLQ-C30 questionnaire. RESULTS: Database records of patients treated in our institution for MPE between October, 2016 and March, 2019. The study included 84 eligible patients. They were categorized with a randomization schedule into treatment group (N = 42) and control group (N = 42). There is statistical significance in the comparison of the total effective rate between these 2 groups (66.67% vs 54.76%, P < .05). Furthermore, there is statistical significance in the comparison of items of Physical (1.95 ± 0.50 vs 2.19 ± 0.58%, P < .05), Pain (1.98 ± 0.42 vs 2.07 ± 0.32, P < .05), and Global Health (1.23 ± 0.64 vs 1.13 ± 0.23%, P < .05) between these 2 groups. None of the patients had adverse reactions such as skin allergy and chest tightness. CONCLUSIONS: The total effective rate of treatment group using extra external application of mirabilite rhubarb powder is significantly higher than that of control group. The improvement of patients’ clinical symptoms is greater in treatment group and no adverse reactions is found. Therefore, external application of mirabilite and rhubarb combined with intrathoracic infusion of cisplatin is an effective method for the treatment of MPE, which is worth popularizing. Lippincott Williams & Wilkins 2021-02-19 /pmc/articles/PMC7899874/ /pubmed/33607823 http://dx.doi.org/10.1097/MD.0000000000024758 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 3800
Zhang, Huachun
Jiang, Mengyuan
Gao, Lirong
Lin, Zhen
The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial
title The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial
title_full The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial
title_fullStr The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial
title_full_unstemmed The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial
title_short The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial
title_sort clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: a prospective, randomized, controlled clinical trial
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899874/
https://www.ncbi.nlm.nih.gov/pubmed/33607823
http://dx.doi.org/10.1097/MD.0000000000024758
work_keys_str_mv AT zhanghuachun theclinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial
AT jiangmengyuan theclinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial
AT gaolirong theclinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial
AT linzhen theclinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial
AT zhanghuachun clinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial
AT jiangmengyuan clinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial
AT gaolirong clinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial
AT linzhen clinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial